NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 130 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.07 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $597,706 | -60.1% | 558,604 | -3.5% | 0.00% | -55.6% |
| Q2 2023 | $1,499,315 | -50.6% | 578,886 | -22.1% | 0.01% | -52.6% |
| Q1 2023 | $3,032,415 | -10.3% | 743,239 | +10.4% | 0.02% | -17.4% |
| Q4 2022 | $3,379,284 | +276.3% | 673,164 | +880.6% | 0.02% | +228.6% |
| Q3 2022 | $898,000 | -83.3% | 68,649 | -80.5% | 0.01% | -80.6% |
| Q1 2022 | $5,367,000 | -29.3% | 351,943 | -17.9% | 0.04% | -29.4% |
| Q4 2021 | $7,587,000 | -21.2% | 428,426 | -6.4% | 0.05% | -21.5% |
| Q3 2021 | $9,626,000 | +93.1% | 457,946 | +81.1% | 0.06% | +91.2% |
| Q2 2021 | $4,986,000 | -25.6% | 252,823 | +9.7% | 0.03% | -34.6% |
| Q1 2021 | $6,700,000 | +1.3% | 230,472 | +5.6% | 0.05% | -10.3% |
| Q4 2020 | $6,611,000 | +81.6% | 218,206 | -4.6% | 0.06% | +52.6% |
| Q3 2020 | $3,641,000 | -7.5% | 228,830 | +14.8% | 0.04% | -11.6% |
| Q2 2020 | $3,936,000 | +131.4% | 199,396 | +44.5% | 0.04% | +95.5% |
| Q1 2020 | $1,701,000 | – | 137,964 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |